<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p24" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_24{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_24{left:341px;bottom:30px;}
#t3_24{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_24{left:377px;bottom:30px;}
#t5_24{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_24{left:540px;bottom:30px;}
#t7_24{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_24{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_24{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_24{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_24{left:285px;bottom:827px;letter-spacing:-0.26px;}
#tc_24{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_24{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_24{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_24{left:1106px;bottom:47px;letter-spacing:0.34px;}
#tg_24{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_24{left:36px;bottom:232px;}
#ti_24{left:46px;bottom:226px;letter-spacing:0.08px;word-spacing:-0.01px;}
#tj_24{left:377px;bottom:226px;letter-spacing:0.12px;}
#tk_24{left:407px;bottom:226px;letter-spacing:0.13px;}
#tl_24{left:481px;bottom:226px;}
#tm_24{left:36px;bottom:215px;}
#tn_24{left:46px;bottom:209px;letter-spacing:0.11px;word-spacing:0.02px;}
#to_24{left:45px;bottom:192px;letter-spacing:0.12px;word-spacing:0.01px;}
#tp_24{left:36px;bottom:182px;}
#tq_24{left:46px;bottom:176px;letter-spacing:0.12px;word-spacing:-0.03px;}
#tr_24{left:557px;bottom:176px;}
#ts_24{left:36px;bottom:165px;}
#tt_24{left:46px;bottom:159px;letter-spacing:0.13px;}
#tu_24{left:36px;bottom:148px;letter-spacing:0.08px;}
#tv_24{left:53px;bottom:142px;letter-spacing:0.13px;}
#tw_24{left:36px;bottom:131px;letter-spacing:-0.83px;}
#tx_24{left:52px;bottom:125px;letter-spacing:0.13px;}
#ty_24{left:36px;bottom:114px;letter-spacing:0.08px;}
#tz_24{left:53px;bottom:108px;letter-spacing:0.1px;word-spacing:0.02px;}
#t10_24{left:438px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.22px;}
#t11_24{left:765px;bottom:786px;}
#t12_24{left:36px;bottom:748px;letter-spacing:-0.24px;}
#t13_24{left:36px;bottom:729px;letter-spacing:-0.1px;}
#t14_24{left:351px;bottom:737px;letter-spacing:-0.13px;}
#t15_24{left:36px;bottom:711px;}
#t16_24{left:47px;bottom:711px;letter-spacing:-0.09px;}
#t17_24{left:36px;bottom:693px;letter-spacing:-0.1px;}
#t18_24{left:42px;bottom:674px;}
#t19_24{left:58px;bottom:674px;letter-spacing:-0.09px;word-spacing:-0.08px;}
#t1a_24{left:571px;bottom:682px;letter-spacing:-0.13px;}
#t1b_24{left:64px;bottom:656px;}
#t1c_24{left:77px;bottom:656px;letter-spacing:-0.09px;}
#t1d_24{left:42px;bottom:638px;}
#t1e_24{left:58px;bottom:638px;letter-spacing:-0.09px;}
#t1f_24{left:64px;bottom:619px;}
#t1g_24{left:77px;bottom:619px;letter-spacing:-0.09px;}
#t1h_24{left:547px;bottom:627px;}
#t1i_24{left:64px;bottom:601px;}
#t1j_24{left:77px;bottom:601px;letter-spacing:-0.09px;}
#t1k_24{left:77px;bottom:583px;letter-spacing:-0.1px;word-spacing:0.01px;}
#t1l_24{left:77px;bottom:564px;letter-spacing:-0.1px;}
#t1m_24{left:458px;bottom:572px;letter-spacing:-0.14px;}
#t1n_24{left:36px;bottom:504px;letter-spacing:-0.09px;}
#t1o_24{left:36px;bottom:486px;letter-spacing:-0.09px;}
#t1p_24{left:36px;bottom:467px;letter-spacing:-0.11px;word-spacing:0.01px;}
#t1q_24{left:611px;bottom:299px;letter-spacing:0.08px;}
#t1r_24{left:628px;bottom:293px;letter-spacing:0.13px;}
#t1s_24{left:619px;bottom:276px;letter-spacing:0.11px;word-spacing:0.02px;}
#t1t_24{left:619px;bottom:260px;letter-spacing:0.1px;word-spacing:0.02px;}
#t1u_24{left:619px;bottom:243px;letter-spacing:0.12px;}
#t1v_24{left:778px;bottom:243px;letter-spacing:0.13px;}
#t1w_24{left:862px;bottom:243px;}
#t1x_24{left:611px;bottom:232px;letter-spacing:0.08px;}
#t1y_24{left:628px;bottom:226px;letter-spacing:0.12px;}
#t1z_24{left:619px;bottom:209px;letter-spacing:0.11px;word-spacing:0.02px;}
#t20_24{left:619px;bottom:192px;letter-spacing:0.1px;word-spacing:0.02px;}
#t21_24{left:619px;bottom:176px;letter-spacing:0.12px;}
#t22_24{left:1041px;bottom:176px;letter-spacing:0.13px;}
#t23_24{left:1125px;bottom:176px;letter-spacing:0.1px;word-spacing:-0.28px;}
#t24_24{left:619px;bottom:159px;letter-spacing:0.12px;}
#t25_24{left:619px;bottom:142px;letter-spacing:0.12px;word-spacing:-0.02px;}
#t26_24{left:619px;bottom:125px;letter-spacing:0.12px;}
#t27_24{left:611px;bottom:114px;letter-spacing:0.08px;}
#t28_24{left:628px;bottom:108px;letter-spacing:0.12px;}
#t29_24{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_24{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_24{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_24{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_24{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_24{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_24{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_24{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_24{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_24{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_24{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sa_24{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sb_24{font-size:17px;font-family:Webdings_k6;color:#000;}
.sc_24{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.sd_24{font-size:15px;font-family:ArialMT_k0;color:#000;}
.se_24{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts24" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg24Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg24" style="-webkit-user-select: none;"><object width="1210" height="935" data="24/24.svg" type="image/svg+xml" id="pdf24" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_24" class="t s0_24">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_24" class="t s1_24">® </span>
<span id="t3_24" class="t s0_24">(NCCN </span>
<span id="t4_24" class="t s1_24">® </span>
<span id="t5_24" class="t s0_24">), All rights reserved. NCCN Guidelines </span>
<span id="t6_24" class="t s1_24">® </span>
<span id="t7_24" class="t s0_24">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_24" class="t s2_24">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_24" class="t s2_24">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_24" class="t s3_24">NCCN Guidelines Version 4.2024 </span>
<span id="tb_24" class="t s3_24">Cancer of the Oropharynx </span>
<span id="tc_24" class="t s4_24">NCCN Guidelines Index </span>
<span id="td_24" class="t s4_24">Table of Contents </span>
<span id="te_24" class="t s4_24">Discussion </span>
<span id="tf_24" class="t s5_24">ORPH-A </span>
<span id="tg_24" class="t s5_24">2 OF 2 </span>
<span id="th_24" class="t s6_24">1 </span>
<span id="ti_24" class="t s7_24">See Principles of Radiation Techniques (RAD-A) </span><span id="tj_24" class="t s8_24">and </span><span id="tk_24" class="t s7_24">Discussion</span><span id="tl_24" class="t s8_24">. </span>
<span id="tm_24" class="t s6_24">4 </span>
<span id="tn_24" class="t s8_24">Suggest 44–50 Gy in 3D-CRT and sequentially planned IMRT or 54–63 Gy with </span>
<span id="to_24" class="t s8_24">IMRT dose painting technique (dependent on dose per fraction). </span>
<span id="tp_24" class="t s6_24">8 </span>
<span id="tq_24" class="t s7_24">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="tr_24" class="t s8_24">. </span>
<span id="ts_24" class="t s6_24">9 </span>
<span id="tt_24" class="t s8_24">Bernier J, et al. N Engl J Med 2004;350:1945-1952. </span>
<span id="tu_24" class="t s6_24">10 </span>
<span id="tv_24" class="t s8_24">Cooper JS, et al. N Engl J Med 2004;350:1937-1944. </span>
<span id="tw_24" class="t s6_24">11 </span>
<span id="tx_24" class="t s8_24">Bernier J, et al. Head Neck 2005;27:843-850. </span>
<span id="ty_24" class="t s6_24">12 </span>
<span id="tz_24" class="t s8_24">Cooper JS, et al. Int J Radiat Oncol Biol Phys 2012;84:1198-1205. </span>
<span id="t10_24" class="t s5_24">PRINCIPLES OF RADIATION THERAPY </span>
<span id="t11_24" class="t s9_24">1 </span>
<span id="t12_24" class="t s5_24">POSTOPERATIVE: </span>
<span id="t13_24" class="t s5_24">RT or Concurrent Systemic Therapy/RT </span>
<span id="t14_24" class="t s9_24">8-12 </span>
<span id="t15_24" class="t s5_24">• </span><span id="t16_24" class="t sa_24">Preferred interval between resection and postoperative RT is ≤6 weeks. </span>
<span id="t17_24" class="t s5_24">• PTV </span>
<span id="t18_24" class="t sb_24"></span><span id="t19_24" class="t s5_24">High risk: Adverse pathologic features such as positive margins </span>
<span id="t1a_24" class="t s9_24">13,14 </span>
<span id="t1b_24" class="t sc_24">◊ </span><span id="t1c_24" class="t s5_24">60–66 Gy (2.0 Gy/fraction); daily Monday–Friday in 6–6.5 weeks </span>
<span id="t1d_24" class="t sb_24"></span><span id="t1e_24" class="t s5_24">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t1f_24" class="t sc_24">◊ </span><span id="t1g_24" class="t s5_24">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t1h_24" class="t s9_24">4 </span>
<span id="t1i_24" class="t sc_24">◊ </span><span id="t1j_24" class="t s5_24">De-escalation to 50 Gy may be considered in patients with p16 (HPV)-positive oropharynx cancer who have up to 4 positive lymph nodes, </span>
<span id="t1k_24" class="t s5_24">T1-T2 resected to negative or close margins (&lt;3 mm), and/or N1–N2 disease (excluding bilateral disease based on ECOG 3311 criteria) </span>
<span id="t1l_24" class="t sa_24">with ≤1 mm extranodal extension (category 2B). </span>
<span id="t1m_24" class="t s9_24">15 </span>
<span id="t1n_24" class="t s5_24">Either IMRT (preferred) or 3D-CRT is recommended for cancers of the oropharynx in order to minimize dose to critical structures. Use of </span>
<span id="t1o_24" class="t s5_24">proton therapy is an area of active investigation. Proton therapy may be considered when normal tissue constraints cannot be met by photon- </span>
<span id="t1p_24" class="t s5_24">based therapy, or when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes. </span>
<span id="t1q_24" class="t s6_24">13 </span>
<span id="t1r_24" class="t s8_24">Adverse pathologic features for p16(HPV)-negative disease: extranodal </span>
<span id="t1s_24" class="t s8_24">extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal </span>
<span id="t1t_24" class="t s8_24">disease, nodal disease in levels IV or V, perineural invasion, vascular invasion, </span>
<span id="t1u_24" class="t s8_24">and lymphatic invasion </span><span id="t1v_24" class="t s7_24">(Discussion)</span><span id="t1w_24" class="t s8_24">. </span>
<span id="t1x_24" class="t s6_24">14 </span>
<span id="t1y_24" class="t s8_24">Adverse pathologic features for p16 (HPV)-positive disease: extranodal </span>
<span id="t1z_24" class="t s8_24">extension, positive margins, close margins (&lt;3 mm), pT3 or pT4 primary, one </span>
<span id="t20_24" class="t s8_24">positive node &gt;3 cm or multiple positive nodes, nodal disease in levels IV or V, </span>
<span id="t21_24" class="t s8_24">perineural invasion, vascular invasion, and lymphatic invasion </span><span id="t22_24" class="t s7_24">(Discussion)</span><span id="t23_24" class="t s8_24">. The </span>
<span id="t24_24" class="t sd_24">definition of an adverse pathologic feature in the context of HPV+ disease is an </span>
<span id="t25_24" class="t s8_24">area of active research. This includes the presence and extent of extranodal </span>
<span id="t26_24" class="t s8_24">extension, and the number of involved nodes. </span>
<span id="t27_24" class="t s6_24">15 </span>
<span id="t28_24" class="t s8_24">Ferris RL, et al. J Clin Oncol 2022;40:138-149. </span>
<span id="t29_24" class="t se_24">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
